DexCom (DXCM) Competitors

Becton, Dickinson and Company (NYSE:BDX) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, community ranking, dividends, valuation and analyst recommendations.

Do insiders and institutionals hold more shares of BDX or DXCM?

87.0% of Becton, Dickinson and Company shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 0.4% of Becton, Dickinson and Company shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Is BDX or DXCM more profitable?

DexCom has a net margin of 14.29% compared to Becton, Dickinson and Company's net margin of 8.47%. DexCom's return on equity of 30.14% beat Becton, Dickinson and Company's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and Company	8.47%	15.74%	7.29%
DexCom	14.29%	30.14%	10.11%

Which has higher earnings and valuation, BDX or DXCM?

Becton, Dickinson and Company has higher revenue and earnings than DexCom. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and Company	$20.64B	2.82	$1.71B	$6.02	33.69
DexCom	$4.03B	6.51	$576.20M	$1.43	46.83

Does the MarketBeat Community favor BDX or DXCM?

DexCom received 379 more outperform votes than Becton, Dickinson and Company when rated by MarketBeat users. Likewise, 71.78% of users gave DexCom an outperform vote while only 62.42% of users gave Becton, Dickinson and Company an outperform vote.

Company	Underperform	Outperform
Becton, Dickinson and Company	Outperform Votes 603 62.42%	Underperform Votes 363 37.58%
DexCom	Outperform Votes 982 71.78%	Underperform Votes 386 28.22%

Do analysts rate BDX or DXCM?

Becton, Dickinson and Company presently has a consensus price target of $275.71, suggesting a potential upside of 35.96%. DexCom has a consensus price target of $99.00, suggesting a potential upside of 47.85%. Given DexCom's higher probable upside, analysts plainly believe DexCom is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and Company	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
DexCom	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.95

Which has more risk and volatility, BDX or DXCM?

Becton, Dickinson and Company has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.

Does the media prefer BDX or DXCM?

In the previous week, DexCom had 2 more articles in the media than Becton, Dickinson and Company. MarketBeat recorded 42 mentions for DexCom and 40 mentions for Becton, Dickinson and Company. DexCom's average media sentiment score of 1.24 beat Becton, Dickinson and Company's score of 1.00 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Becton, Dickinson and Company	26 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
DexCom	23 Very Positive mention(s)	6 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DexCom beats Becton, Dickinson and Company on 14 of the 19 factors compared between the two stocks.